Promising research suggests retatrutide, a innovative dual-action peptide, could be a significant advance in metabolic management. This compound works by activating both the GLP-1 and GIP receptors, conceivably offering a greater benefit than existing GLP-1 receptor therapies. Early clinical … Read More